Enanta Pharmaceuticals | ENTA - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Amgen USD 92.5B 1.92B 2026-03
Anika Therapeutics USD 179.39M 10.88M 2026-03
Arrowhead Research USD 2.27B 664.08M 2026-03
AstraZeneca USD 114.02B 59M 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Biogen USD 29.48B 43.6M 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Heron Therapeutics USD 246.22M 9.66M 2026-03
Immunic USD 189.74M 165.69M 2026-03
Incyte USD 7.34B 381.14M 2026-03
Insmed USD 2.08B 188.7M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
J&J USD 200.89B 1.68B 2026-03
Karyopharm Therapeutics USD 108.42M 12.18M 2025-12
Ligand Pharmaceuticals USD 1.53B 28.53M 2026-03
Merck USD 128.68B 8.18B 2026-03
Neurocrine Biosciences USD 4.91B 274.7M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Novavax USD 1.04B 133.35M 2026-03
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03